News | May 13, 2021
Eris Lifesciences reports Q4FY21 consolidated net profit of Rs. 68.24 Cr
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
The agreement will help ensure wider reach and access to patients in India
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Subscribe To Our Newsletter & Stay Updated
